Tag: saxagliptin
-
Pancreatic Cancer Associated With Use Of Diabetes Medicines In DPP-4 Inhibitor Drug Class
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study (Posted by Tom Lamb at DrugInjuryWatch.com) Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated…
-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza And Kombiglyze XR
April 2015 FDA Advisory Committee Voted For An Onglyza Drug Label Change About Side Effects Risks, With One Panelist Voting Of An Onglyza Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As previewed…
-
Diabetes Drugs Kombiglyze And Onglyza: Heart Failure Side Effect Seems To Be Valid, And FDA Notes There Is A Possible Increased Risk Of All-Cause Mortality
As Analysis Did Not Reveal Causes Of The Increase In Death Incidents, FDA Asks Its Advisory Committee To Discuss This Safety Issue At April 2015 Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "AstraZeneca, Takeda Diabetes Drugs…
-
Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting
These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com)At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, results of the…
-
Possible Link Between Heart Failure And Onglyza Diabetes Type 2 Drug Is Being Investigated By FDA, As Announced In February 2014
This Cardiovascular Side Effect Issue Also Involves Kombiglyze XR, A Saxagliptin – Metformin Combo Diabetes Medication (Posted by Tom Lamb at DrugInjuryWatch.com)AstraZeneca's diabetes drugs Onglyza and Kombiglyze, both of which contain the active ingredient saxagliptin,…
-
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza — Little Is Known About Long-Term Effects
As “Pancreatitis Is On The Pathway Toward Pancreatic Cancer”, Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE: “Cancer of The Pancreas:…